United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - ramipril - oral capsule - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - ramipril - oral capsule - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - omeprazole - gastro-resistant capsule - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

focus pharmaceuticals ltd - ramipril - oral capsule - 10mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - celecoxib 100mg;  ;   - capsule - 100 mg - active: celecoxib 100mg     excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate povidone sodium laurilsulfate - symptomatic treatment of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. for the management of acute pain and treatment of primary dysmenorrhoea in adults. the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapies have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient, and · after assessment of the individual patient's overall risks. as the cardiovascular risks of the selective cox-2 inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. patients on long-term treatment should be reviewed regularly, such as every three months, with regards to efficacy, risk factors and ongoing need for treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - celecoxib 200mg;  ;   - capsule - 200 mg - active: celecoxib 200mg     excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate povidone sodium laurilsulfate - symptomatic treatment of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. for the management of acute pain and treatment of primary dysmenorrhoea in adults. the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapies have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient, and · after assessment of the individual patient's overall risks. as the cardiovascular risks of the selective cox-2 inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. patients on long-term treatment should be reviewed regularly, such as every three months, with regards to efficacy, risk factors and ongoing need for treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - celecoxib 400mg;   - capsule - 400 mg - active: celecoxib 400mg   excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate povidone sodium laurilsulfate tekprint green sb-4027 titanium dioxide - symptomatic treatment of pain and inflammation in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. for the management of acute pain and treatment of primary dysmenorrhoea in adults. the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapies have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient, and · after assessment of the individual patient's overall risks. as the cardiovascular risks of the selective cox-2 inhibitors may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. patients on long-term treatment should be reviewed regularly, such as every three months, with regards to efficacy, risk factors and ongoing need for treatment.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - omeprazole - gastro-resistant capsule - 40mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ivax pharmaceuticals uk ltd - omeprazole - gastro-resistant capsule - 40mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - omeprazole - gastro-resistant capsule - 40mg